Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Ulrich Jaeger, MD, Alexander Egle, MD, Ingrid Simonitsch-Klupp, MD, Sonja Heibl, MD, Peter Neumeister, MD, Ella Willenbacher, MD, Florian Erlsbacher, Julian Larcher-Senn, Michael A. Fridrik, MD, Richard Greil, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-136953

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

https://doi.org/10.1182/blood-2019-128388

Published: 2019

Journal Articles

Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL

Katrin Pansy, MSc, BSc, Julia Feichtinger, Barbara Ehall, Barbara Uhl, Hildegard T. Greinix, MD, Katharina Prochazka, MD, Christine Beham-Schmid, Peter Neumeister, MD, Tanja Wrodnigg, Karoline Fechter, Alexander Deutsch

Blood (2019) 134 (Supplement_1): 1519.

https://doi.org/10.1182/blood-2019-130029

Published: 2019

Journal Articles

Evaluation of Clinical and Morphological Practices in the Diagnosis of Transplant-Associated Microangiopathy: A Study on Behalf of the Complications and Quality of Life Working Party of the EBMT

Blood (2017) 130 (Supplement 1): 1958.

https://doi.org/10.1182/blood.V130.Suppl_1.1958.1958

Published: 2017

Journal Articles

NR4A3 Suppresses Lymphomagenesis I n Vitro and In Vivo by Induction of Similar Patterns of Pro-Apoptotic Genes like NR4A1

Alexander JA Deutsch, PhD, Beate Rinner, Martin Pichler, Karoline Fechter, Hildegard T. Greinix, MD, Chenguang Wang, Christine Beham-Schmid, MD, Peter Neumeister, MD

Blood (2016) 128 (22): 2728.

https://doi.org/10.1182/blood.V128.22.2728.2728

Published: 2016

Journal Articles

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Michael Panny, MD, Katharina Troppan, MD, Peter Neumeister, MD, Thomas Nösslinger, MD, Felix Keil, MD

Blood (2016) 128 (22): 5413.

https://doi.org/10.1182/blood.V128.22.5413.5413

Published: 2016

Journal Articles

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

Kerstin Wenzl, MSc, Katharina Troppan, MD, Beata Pursche, Marco Bischof, Christine Beham-Schmid, MD, Hildegard T. Greinix, MD, Peter Neumeister, MD, Alexander JA Deutsch, PhD

Blood (2015) 126 (23): 2444.

https://doi.org/10.1182/blood.V126.23.2444.2444

Published: 2015

Journal Articles

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

Barbara Kiesewetter, MD, Richard Greil, MD, Wolfgang Willenbacher, MD, Peter Neumeister, MD, Michael A. Fridrik, MD, Raderer Markus, MD

Blood (2015) 126 (23): 3973.

https://doi.org/10.1182/blood.V126.23.3973.3973

Published: 2015

Journal Articles

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

Katharina Troppan, MD, Kerstin Wenzl, MSc, Peter Neumeister, MD, Christine Beham-Schmid, MD, Martina Przekopowitz, Hildegard T. Greinix, MD, Helmut Schaider, MD, Alexander JA Deutsch, PhD

Blood (2015) 126 (23): 3890.

https://doi.org/10.1182/blood.V126.23.3890.3890

Published: 2015

Journal Articles

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

Alexander JA Deutsch, PhD, Beate Rinner, PhD, Kerstin Wenzl, MSc, Katharina Troppan, MD, Beata Pursche, Hildegard T. Greinix, MD, Christine Beham-Schmid, MD, Peter Neumeister, MD

Blood (2015) 126 (23): 2674.

https://doi.org/10.1182/blood.V126.23.2674.2674

Published: 2015

Journal Articles

Distinct Chemokine Receptor Profile In Chronic Lymphocytic Leukaemia and Richter Transformed Diffuse Large B Cell Lymphomas Compared To Germinal Center B Cells and De Novo Diffuse Large B Cell Lymphomas

Kerstin Wenzl, MSc, Katharina Troppan, MD, Alexander JA Deutsch, Werner Linkesch, MD, Peter Neumeister, MD, Christine Beham-Schmid, MD

Blood (2013) 122 (21): 4852.

https://doi.org/10.1182/blood.V122.21.4852.4852

Published: 2013

Journal Articles

Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Wolfgang Willenbacher, MD, Ferdinand Haslbauer, MD, Peter Neumeister, MD, Anton Guttmann, MD, Roland Sperb, MD, Andreas Lohri, MD, Biagio Saldutto, lic. phil. I, Christine Jaeger, PhD, Carine Bast, MSc, Christoph Renner, MD

Blood (2013) 122 (21): 4855.

https://doi.org/10.1182/blood.V122.21.4855.4855

Published: 2013

Journal Articles

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

Andreas Tiede, MD, PhD, Jan-Malte Blumtritt, Robert Klamroth, MD, PhD, Saskia Gottstein, MD, Katharina Holstein, MD, Jürgen Heinz, MD, Rüdiger E. Scharf, MD, PhD, Angela Huth-Kühne, MD, PhD, Joachim F. Schenk, MD, PhD, Richard Greil, MD, Wolfgang A. Miesbach, MD, PhD, Ralf Ulrich Trappe, MD, PhD, Ute Scholz, MD, Daniela Manner, MD, Peter Neumeister, MD, Charis von Auer-Wegener, MD, Ulrich Kalus, MD, Klaus Leimkühler, MD, Paul Knoebl, MD

Blood (2013) 122 (21): 205.

https://doi.org/10.1182/blood.V122.21.205.205

Published: 2013

Journal Articles

The Nuclear Orphan Receptors NR4A1 and NR4A3 as Putative Tumour Suppressor Genes in Aggressive Non-Hodgkin's Lymphomas.

Alexander JA Deutsch, Christine Beham-Schmid, Werner Linkesch, MD, Peter Neumeister, MD

Blood (2009) 114 (22): 2967.

https://doi.org/10.1182/blood.V114.22.2967.2967

Published: 2009

Journal Articles

Relapsed MALT Lymphomas Are Associated with a Restricted VH3-30.3 Immunoglobulin VH Gene Repertoire and Are Targeted by Aberrant Somatic Hypermutation

Alexander JA Deutsch, Ruth I Brezinschek, Hans-Peter Brezinschek, Christine Beham-Schmid, Peter Neumeister, MD

Blood (2008) 112 (11): 2830.

https://doi.org/10.1182/blood.V112.11.2830.2830

Published: 2008

Journal Articles

Chemokine Receptor Expression Profile in the Model of Parotid MALT Lymphomagenesis: De Novo Expression of CXCR6.

Alexander J.A. Deutsch, MSc, Ariane Aigelsreiter, MD, Elisabeth Steinbauer, Werner Linkesch, MD, Christine Beham-Schmid, MD, Helmut Schaider, MD, Peter Neumeister, MD

Blood (2007) 110 (11): 2622.

https://doi.org/10.1182/blood.V110.11.2622.2622

Published: 2007

Journal Articles

Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.

Stefan Langner, MD, Philipp B. Staber, MD, Armin Zebisch, MD, Wilma Zinke-Cerwenka, MD, Heinz Sill, MD, Werner Linkesch, MD, Hildegard Greinix, MD, Peter Kalhs, MD, Werner Rabitsch, MD, Peter Neumeister, MD

Blood (2006) 108 (11): 5251.

https://doi.org/10.1182/blood.V108.11.5251.5251

Published: 2006

Journal Articles

Aberrant Somatic Hypermutation in Extranodal Marginal Zone B-Cell Lymphoma of MALT Type.

Alexander Deutsch, BA, Ariane Aigelsreiter, MD, Christine Beham-Schmid, MD, Alfred Beham, MD, Werner Linkesch, MD, Peter Neumeister, MD

Blood (2005) 106 (11): 417.

https://doi.org/10.1182/blood.V106.11.417.417

Published: 2005

Journal Articles

Pegfilgrastim Shows Safety and Efficacy Similar to Filgrastim in Patients Undergoing Autologous Stem Cell Transplantation for Hematological Malignancies.

Peter Neumeister, MD, Robert Holub, MD, Phillipe B. Staber, MD, Werner Linkesch, MD

Blood (2004) 104 (11): 1156.

https://doi.org/10.1182/blood.V104.11.1156.1156

Published: 2004

NARROW

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL

Evaluation of Clinical and Morphological Practices in the Diagnosis of Transplant-Associated Microangiopathy: A Study on Behalf of the Complications and Quality of Life Working Party of the EBMT

NR4A3 Suppresses Lymphomagenesis I n Vitro and In Vivo by Induction of Similar Patterns of Pro-Apoptotic Genes like NR4A1

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

Distinct Chemokine Receptor Profile In Chronic Lymphocytic Leukaemia and Richter Transformed Diffuse Large B Cell Lymphomas Compared To Germinal Center B Cells and De Novo Diffuse Large B Cell Lymphomas

Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

The Nuclear Orphan Receptors NR4A1 and NR4A3 as Putative Tumour Suppressor Genes in Aggressive Non-Hodgkin's Lymphomas.

Relapsed MALT Lymphomas Are Associated with a Restricted VH3-30.3 Immunoglobulin VH Gene Repertoire and Are Targeted by Aberrant Somatic Hypermutation

Chemokine Receptor Expression Profile in the Model of Parotid MALT Lymphomagenesis: De Novo Expression of CXCR6.

Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.

Aberrant Somatic Hypermutation in Extranodal Marginal Zone B-Cell Lymphoma of MALT Type.

Pegfilgrastim Shows Safety and Efficacy Similar to Filgrastim in Patients Undergoing Autologous Stem Cell Transplantation for Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only